Go Back Up

back to blog

Pfizer and BioNTech’s COVID-19 vaccine 90% effective

Medical Pharmaceutical Translations • Nov 16, 2020 12:00:00 AM

A ray of hope pierced the gloom last week, when Pfizer and BioNTech announced that phase III testing data appears to show that their COVID-19 vaccine is 90% effective.

The trial involved over 43,000 participants, some of whom received the vaccine, in two doses, while others received a placebo. Of those who were vaccinated, 90% were immune to the novel coronavirus 7 days after being given the second dose.

That said, we still have a few months at least before the vaccine would be released to the public. During that time, Pfizer and BioNTech will continue testing and examining the safety of the vaccine. Participants will also have to be tested 7 more days after the initial tests to see if they’re still immune to the virus.

Read on to learn more about this very promising news, and how the trials and testing process will continue.

Image source

Contact Our Writer – Alysa Salzberg

Ready to Transform your Business with Little Effort Using Vertical?

Alysa Salzberg